Christopher T. Ritchlin
University of Rochester Medical Center
392 Papers
2.1K Citations
Christopher T. Ritchlin is an academic researcher from University of Rochester Medical Center. The author has contributed to research in topics: Psoriatic arthritis & Medicine. The author has an hindex of 62, co-authored 322 publications. Previous affiliations of Christopher T. Ritchlin include University College Dublin & University of Toronto.
Chat about Author
Papers
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trial
Philip J. Mease,Dafna D. Gladman,Christopher T. Ritchlin,Eric Ruderman,Serge Steinfeld,Ernest Choy,John T. Sharp,Peter A. Ory,Renee J. Perdok,M A Weinberg +9 more
TL;DR: Adalimumab significantly improved joint and skin manifestations, inhibited structural changes on radiographs, lessened disability due to joint damage, and improved quality of life in patients with moderately to severely active PsA.
953
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis
Laura C. Coates,Arthur Kavanaugh,Philip J. Mease,Enrique R. Soriano,Maria Laura Acosta-Felquer,April W. Armstrong,Wilson Bautista-Molano,Wolf-Henning Boehncke,Willemina Campbell,Alberto Cauli,Luis R. Espinoza,Oliver FitzGerald,Dafna D. Gladman,Alice B. Gottlieb,Philip S. Helliwell,M. Elaine Husni,Thorvardur Jon Love,Ennio Lubrano,Neil McHugh,Peter Nash,Alexis Ogdie,Ana Maria Orbai,Andrew Parkinson,Denis O'Sullivan,Cheryl F. Rosen,Sergio Schwartzman,Evan L. Siegel,Sergio Toloza,William Tuong,Christopher T. Ritchlin +29 more
TL;DR: To update the 2009 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations for the spectrum of manifestations affecting patients with psoriatic arthritis (PsA).
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2) : a randomised, double-blind, placebo-controlled, phase 3 trial
Iain B. McInnes,Philip J. Mease,Bruce Kirkham,Arthur Kavanaugh,Christopher T. Ritchlin,Proton Rahman,Désirée van der Heijde,Robert Landewé,Philip G. Conaghan,Alice B. Gottlieb,Hanno B. Richards,Luminita Pricop,Gregory Ligozio,Manmath Patekar,Shephard Mpofu +14 more
TL;DR: Subcutaneous secukinumab 300 mg and 150 mg improved the signs and symptoms of psoriatic arthritis, suggesting that secuk inumab is a potential future treatment option for patients with this disorder.
806
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
Iain B. McInnes,Arthur Kavanaugh,Alice B. Gottlieb,Lluís Puig,Proton Rahman,Christopher T. Ritchlin,Carrie Brodmerkel,Shu Li,Y. Wang,Alan M. Mendelsohn,Mittie K. Doyle +10 more
TL;DR: Ustekinumab significantly improved active psoriatic arthritis compared with placebo, and might offer an alternative therapeutic mechanism of action to approved biological treatments.
775
Treatment recommendations for psoriatic arthritis
Christopher T. Ritchlin,Arthur Kavanaugh,Dafna D. Gladman,Philip J. Mease,Philip S. Helliwell,Wolf-Henning Boehncke,K. de Vlam,David Fiorentino,Oliver FitzGerald,Alice B. Gottlieb,Neil McHugh,Peter Nash,Abrar A. Qureshi,Enrique R. Soriano,William J. Taylor +14 more
TL;DR: Treatment recommendations for the cardinal physical manifestations of PsA were developed based on a literature review and consensus between rheumatologists and dermatologists and a grid was established to assist in therapeutic reasoning and decision making for individual patients.
761